Marina Biotech (formerly MDRNA/Nastech) is offering intellectual property related to intranasal formulations of rapid-acting insulin and of parathyroid hormone (PTH) for the treatment of osteoporosis for sale through ICAP Patent Brokerage. ICAP has recently handled a number of portfolios related to inhalation and nasal delivery, offering several at live auction in … [Read more...] about Intranasal insulin and PTH formulations for sale
News
Phase 3 studies presented at ERS show efficacy and safety of Flutiform
According to Mundipharma, three Phase 3 studies of the Flutiform fluticasone propionate/formoterol fumarate metered dose inhaler (MDI) have demonstrated that the product "had comparable efficacy in improving the lung function and a similar safety profile to budesonide/formoterol, a licensed combination asthma therapy," "was as effective in treating asthma as … [Read more...] about Phase 3 studies presented at ERS show efficacy and safety of Flutiform
Positive Phase 2a results for Elevation’s glycopyrrolate inhalation solution
Elevation Pharmaceuticals has presented positive results from a Phase 2a study of its glycopyrrolate inhalation solution in patients with moderate to severe COPD at the European Respiratory Society (ERS) meeting in Amsterdam. If Elevation can bring the formulation, known as EP-101, to market, it would be the first long-acting muscarinic antagonist (LAMA) available for … [Read more...] about Positive Phase 2a results for Elevation’s glycopyrrolate inhalation solution
MannKind looking to raise $370 million for continued development of Afrezza
MannKind Corporation has announced a proposed offer of senior secured discount notes, due 2017, that would yield approximately $370 million. The company says that it would use the money to complete Phase 3 clinical trials of its Afrezza inhaled insulin, to prepare for commercialization of the product, and for work on its manufacturing plant in Danbury, CT, among other … [Read more...] about MannKind looking to raise $370 million for continued development of Afrezza
TOBI Podhaler DPI launched in UK
Novartis has launched its TOBI Podhaler tobramycin dry powder inhaler in the UK. The DPI, for the treatment of P. aeruginosa infections in cystic fibrosis patients. The CF Trust responded to the launch on its website, noting "This is the first ever antibiotic pod haler and is a development the CF Trust welcomes." Read a brief article. … [Read more...] about TOBI Podhaler DPI launched in UK
Website for AirPROM consortium launched
The European Lung Foundation has launched a website for its AirPROM consortium, a group formed "to integrate and enhance the capacities of all partners to deliver the best possible outcome for people with asthma and chronic obstructive pulmonary disease (COPD)." The AirPROM name stands for "Airway Disease Predicting Outcomes through Patient Specific Computational … [Read more...] about Website for AirPROM consortium launched
New aerosol measurement book available
Research and Markets is now offering a new 904-page edition of Aerosol Measurement: Principles, Techniques, and Applications edited by Pramod Kulkarni, Paul Baron, and Klaus Willeke, and published by John Wiley and Sons. This is the 3rd edition of the book, which includes chapters on basic principles, techniques, and applications. The latter section includes a chapter … [Read more...] about New aerosol measurement book available
American Academy of Family Physicians calls for affordable inhalers
The Congress of Delegates of the American Academy of Family Physicians (AAFP) has approved a resolution calling for the organization "to work with public and private payers to ensure the lowest copays for at least one inhaled steroid and one short-acting, beta adrenergic inhaler in their drug formularies with any copays at the lowest tier level, and one … [Read more...] about American Academy of Family Physicians calls for affordable inhalers
Southwest Research Institute gets $4.4 million for development of intranasal cyanide antidote
The US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) has awarded a $4.4 million contract to Texas-based Southwest Research Institute (SwRI), an independent applied research and development organization, for development of an intranasal cyanide antidote. The only treatments for cyanide poisoning currently … [Read more...] about Southwest Research Institute gets $4.4 million for development of intranasal cyanide antidote
Sun Pharma says it will file IND for Starhaler in 2012
During its presentation at the 2011 Morgan Stanley Global Healthcare Conference on September 14, Sun Pharma Advanced Research Company (SPARC) provided a detailed report on the development of its Starhaler dry powder inhaler and announced that it plans to file an investigational new drug (IND) application in the US in 2012. The company, which co-developed the device … [Read more...] about Sun Pharma says it will file IND for Starhaler in 2012